ZYME

ZYME

USD

Zymeworks Inc. Common Stock

$18.160-0.230 (-1.251%)

वास्तविक समय मूल्य

Healthcare
जैव प्रौद्योगिकी
संयुक्त राज्य अमेरिका

मूल्य चार्ट

Loading Chart...

मुख्य मीट्रिक्स

बाजार मीट्रिक्स
कंपनी के मौलिक सिद्धांत
ट्रेडिंग आँकड़े

बाजार मीट्रिक्स

खुलना

$18.390

उच्च

$18.770

कम

$18.000

मात्रा

0.08M

कंपनी के मौलिक सिद्धांत

बाजार पूंजीकरण

1.4B

उद्योग

जैव प्रौद्योगिकी

देश

United States

ट्रेडिंग आँकड़े

औसत मात्रा

0.66M

एक्सचेंज

NMS

मुद्रा

USD

52-सप्ताह रेंज

कम $9.03वर्तमान $18.160उच्च $19.98

संबंधित समाचार

GlobeNewswire

Zymeworks Announces Participation in Upcoming Investor Conferences

VANCOUVER, British Columbia, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the

और देखें
Zymeworks Announces Participation in Upcoming Investor Conferences
GlobeNewswire

Zymeworks Presents Initial Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺ at AACR-NCI-EORTC Conference

Preliminary efficacy data, combined with a tolerable safety profile, reinforce the potential of ZW191 in patients with advanced solid tumors, including ovarian, endometrial, and non-small cell lung cancer64% overall

और देखें
Zymeworks Presents Initial Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺ at AACR-NCI-EORTC Conference
Analyst Upgrades

HC Wainwright & Co. Upgrades Zymeworks to Buy, Raises Price Target to $26

HC Wainwright & Co. analyst Robert Burns upgrades Zymeworks from Neutral to Buy and raises the price target from $13 to $26.

और देखें
HC Wainwright & Co. Upgrades Zymeworks to Buy, Raises Price Target to $26
GlobeNewswire

Zymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺, at AACR-NCI-EORTC International Conference

Preliminary data presented at the AACR-NCI-EORTC conference will provide insights into the potential of ZW191 in patients with advanced solid tumors, including ovarian cancer, endometrial cancer, and non-small cell lung

और देखें
Zymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺, at AACR-NCI-EORTC International Conference
Analyst Upgrades

B. Riley Securities Initiates Coverage On Zymeworks with Buy Rating, Announces Price Target of $30

B. Riley Securities analyst Mayank Mamtani initiates coverage on Zymeworks with a Buy rating and announces Price Target of $30.

और देखें
B. Riley Securities Initiates Coverage On Zymeworks with Buy Rating, Announces Price Target of $30
GlobeNewswire

Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer

VANCOUVER, British Columbia, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the

अपडेट रहें

मूल्य अलर्ट सेट करें, AI विश्लेषण अपडेट और वास्तविक समय बाजार समाचार प्राप्त करें।